Cryoport Q3 revenue rises driven by growth in cell & gene therapy , raises 2025 revenue forecast

CryoPort

04/11/2025 21:39

Overview

Cryoport Q3 revenue rises 15% yr/yr, driven by cell & gene therapy growth

Company updates full-year 2025 revenue guidance to $170-$174 mln

Cryoport reports Q3 net loss of $8.9 mln

Company repurchased 483,397 shares for $3.7 mln in Q3

Outlook

Cryoport raises full-year 2025 revenue guidance to $170 mln-$174 mln

Company anticipates growth from DHL partnership and new supply chain centers

Cryoport's 2025 guidance depends on economic and geopolitical factors

Result Drivers

CELL & GENE THERAPY - Revenue from commercial cell & gene therapies grew 36% yr/yr, contributing significantly to Q3 results

BIOSTORAGE/BIOSERVICES - Life Sciences Services revenue increased 16% yr/yr, with BioStorage/BioServices revenue up 21%, reflecting strong demand

CRYOGENIC SYSTEMS - Life Sciences Products revenue grew 15% yr/yr, supported by sustained demand for cryogenic systems

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$8.90 mln
Q3 Gross Margin
48.20%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the courier, postal, air freight & land-based logistics peer group is "buy"

Wall Street's median 12-month price target for Cryoport Inc is $13.00, about 30.5% above its November 3 closing price of $9.04

Press Release: ID:nPn9gSqFfa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)